Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Microglial SWELL1 deficiency drives male-specific seizure vulnerability but paradoxical neuroprotection through impaired phagocytosis
Abhijeet S. Barath, Aastha Dheer, Laura Montier, Mekenzie M Peshoff, Emily Dale, Flavia Goche, Thanh Thanh Le Nguyen, Mastura Akter, FangFang Qi, Dimitrios Kleidonas, Lauren Harris, Sarah A. Jewanee, Anthony D. Umpierre, Dale B. Bosco, Koichiro Haruwaka, Rajan Sah, Long-Jun Wu
Abhijeet S. Barath, Aastha Dheer, Laura Montier, Mekenzie M Peshoff, Emily Dale, Flavia Goche, Thanh Thanh Le Nguyen, Mastura Akter, FangFang Qi, Dimitrios Kleidonas, Lauren Harris, Sarah A. Jewanee, Anthony D. Umpierre, Dale B. Bosco, Koichiro Haruwaka, Rajan Sah, Long-Jun Wu
View: Text | PDF
Research Article Immunology Neuroscience

Microglial SWELL1 deficiency drives male-specific seizure vulnerability but paradoxical neuroprotection through impaired phagocytosis

  • Text
  • PDF
Abstract

The discovery of genes encoding the volume-regulated anion channel (VRAC) has enabled detailed exploration of its cell type–specific roles in the brain. LRRC8A (SWELL1) is the essential VRAC subunit. We observed seizure-induced, subunit-specific changes in microglial VRAC expression and investigated its function using conditional KO (cKO) of LRRC8A in microglia. SWELL1 cKO mice exhibited a male-specific increase in kainate-induced seizure severity, yet showed paradoxical neuroprotection against seizure-associated neuronal loss. Mechanistically, SWELL1 deletion led to a cell-autonomous reduction in microglial density and decreased release of VRAC-permeable neuroactive metabolites, including taurine, GABA, and glutamate in culture. Additionally, impaired phagocytic kinetics and reduced lysosomal biogenesis contributed to the observed neuroprotection. These findings reveal potentially novel roles for microglial VRAC in regulating seizure outcomes and microglia-neuron interactions.

Authors

Abhijeet S. Barath, Aastha Dheer, Laura Montier, Mekenzie M Peshoff, Emily Dale, Flavia Goche, Thanh Thanh Le Nguyen, Mastura Akter, FangFang Qi, Dimitrios Kleidonas, Lauren Harris, Sarah A. Jewanee, Anthony D. Umpierre, Dale B. Bosco, Koichiro Haruwaka, Rajan Sah, Long-Jun Wu

×

Figure 1

Bidirectional interplay between microglial VRAC expression and seizure severity.

Options: View larger image (or click on image) Download as PowerPoint
Bidirectional interplay between microglial VRAC expression and seizure s...
(A) A dot plot showing changes in microglial homeostatic, epilepsy-related, and Lrrc8 family genes at day 7 after kainate-induced seizure in WT mice (bulk sequencing of brain CD11b+ cells; n = 4–5 WT mice/group). (B) Lrrc8a-Lrrc8d expression in microglia at day 7 after seizures (statistic: q value [i.e., FDR-adjusted P value]). (C) Swell1 cKO mouse stop codons are placed around the E3 exon, which is spliced out after tamoxifen or 4-OHT treatment. tdTomato expression is also activated. (D) Relative Swell1 mRNA levels in CD11b+ and CD11b– cells showing cKO efficiency and selectivity (mRNA normalized to GAPDH) versus control animals treated with tamoxifen (statistic: Mann-Whitney U test and unpaired 2-tailed t test). (E) Seizure experiment timeline. (F) Longitudinal Racine seizure scores in SWELL1 cKO versus littermate controls (n = 25–35 mice/group; statistic: 2-way ANOVA). (G) Average seizure scores over the 2-hour observation period (statistic: unpaired 2-tailed t test). (H) Percentage of mice achieving a Racine score of 5 or higher at least once. (I) Survival rate. 4-OHT: 4-hydroxy tamoxifen (active metabolite of tamoxifen); FPKM, fragments per kilobase of exon per million mapped fragments; ICV, intracerebroventricular; KA, kainate; LM, vehicle-treated littermate controls; Tam, tamoxifen-treated controls. *P <0.05, **P <0.01, ***P or q <0.005, ****P or q <0.001

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts